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Aim. To evaluate whether angioplasty or above-knee bypass is the best treatment for symptomatic superficial femoral artery
occlusive lesions, we performed a multicentre randomised trial.
Patients and methods. Between October 1995 and August 1998, 56 patients were enrolled, all with symptoms related to a
5–15 cm long occlusive lesion of the superficial femoral artery. Thirty-one patients were randomly assigned to percutaneous
transluminal angioplasty (PTA); 25 patients to bypass surgery. All patients were followed at 1, 6 and 12 months after the
procedure. The primary outcome of our study was re-occlusion of the femoral artery.
Results. Thirty patients underwent the allocated PTA and 24 patients underwent bypass surgery. Cumulative 1-year
primary patency after PTAwas 43 and 82% after bypass surgery. After PTAmore than half of the patients had a re-occlusion
with an absolute risk reduction of 31% (CI: 6–56%) in favour of bypass surgery. The hazard ratio for occlusion comparing
PTA with bypass surgery is 2.24 (95% CI: 0.9–5.58).
Conclusion. Despite 18 participating centres only 56 patients were randomised to PTA our bypass surgery. Based on our
results, for every three patients treated with bypass surgery instead of PTA, one additional re-occlusion is prevented.
Therefore, we conclude that with respect to patency, for long superficial femoral artery (SFA) stenoses or occlusions, surgery
is better than PTA.
Key Words: Randomised trial; Percutaneous transluminal angioplasty; Bypass surgery; Femoro-popliteal occlusive disease;
Primary patency; SVS/ISCVS classification; ARR; NNT.
Introduction
Intermittent claudication is usually treated conserva-
tively. However, if conservative treatment fails and the
patient is strongly disabled, invasive treatment can be
considered. percutaneous transluminal angioplasty
(PTA) or bypass surgery are the possible treatment
options for patients with an isolated lesion of the
superficial femoral artery (SFA). The optimal method
of treatment remains controversial because both
treatment modalities have never been compared in a
well-defined randomised trial.1 Meta-analysis of
observational cohort studies showed a pooled one-
year primary patency of PTA of 85% (83–86%) against
95% (94–97%) for vein bypass surgery. After 3 years
follow-up the difference in primary patency increased
to 13% (75% (72–78%) versus 89% (86–91%), respect-
ively).2 It should be emphasised that this is not a
randomised comparison.
A decision-analysis, based on the results of these
cohort studies, advised PTA for stenosis or short
occlusions of the SFA, whereas vein bypass surgery
was recommended for long occlusions.3 However, this
recommendation was based on heterogeneous patient
groups. Because of the lack of well-defined study
groups, we decided to perform a multi-centre ran-
domised clinical trial with a homogeneous patient
group, according to suggested standards.4,5
The aim of this BASIC trial (Bypass or Angioplasty in
Severe Intermittent Claudication) was to evaluate
whether PTA or vein bypass is the most successful
treatment for patients with an isolated SFA lesionwith a
length between 5 and 15 cm combined with symptoms
classified according to the SVS/ISCVS classification.
Patients and Methods
Patients
Patients had to fulfil two inclusion criteria: intermit-
tent claudication not responding to conservative
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therapy for at least 3 months and a stenosis or
occlusion of the SFA with a length between 5 and
15 cm. Results of a baseline treadmill test and
symptoms were recorded according to the SVS/ISCVS
classification. A digital subtraction angiography was
used for baseline assessment of the SFA and the
outflow arteries. Exclusion criteria were: a hemody-
namically significant stenosis of the aorto-iliac tract as
detected by duplex scanning, absence of patent crural
arteries, previous treatment of the femoropopliteal
segment, life expectancy less than one year due to
concomitant diseases and contra-indication for PTA or
surgery, such as severe cardiopulmonary diseases.
Methods
Principal investigators of 18 participating centres in
the Netherlands (16) and United Kingdom (2) con-
sented to participate in this randomised trial. The
ethical committee of all participating centres approved
the study protocol. All patients signed written
informed consent before randomisation. Patients
were assigned to PTA or vein bypass by computer
randomisation, stratified for each centre.
The PTA was carried out by conventional balloon
dilatation of the lesion. A stent could be placed,
according to the decision of the interventional radiol-
ogist. If the PTA procedure technically failed the
patient received a bypass graft. The bypass procedure
was performed according to standard vascular tech-
niques, using an in situ or reversed autogenous vein
graft. Both treatment groups received Aspirin 100 mg
daily after treatment for at least 3 months. For both
procedures hemodynamic significant re-stenosis or
occlusion were treated either by PTA or bypass,
according to the decision of the responsible surgeon.
Follow-up continued after a redo-procedure. The
patients were followed in a thorough non-invasive
surveillance program consisting of a quality of life
questionnaire, physical examination, blood systolic
pressure measurements, treadmill test and duplex
scan of the target limb. These visits were performed at
1, 6 and 12 months after the procedure and every
following year or if symptoms reoccurred. The blood
systolic ankle pressure and ankle brachial index (ABI)
were assessed at rest and immediately after treadmill-
exercise. The treadmill test was standardised: 5 min at
3 km/h, with an eight percent incline.4,5 Patency of the
treated vessel or bypass was established via duplex
scanning by calculating the peak systolic velocity
(PSV) and the end diastolic velocity (EDV). Both
parameters were used to trace the diameter reduction
of the revascularized artery. An increase of the PSV
greater then 2.5 at a stenosis site was defined as
hemodynamically significant.6
Analysis
The primary outcome of our study was re-occlusion of
the femoral segment. We assumed that venous bypass
surgery is more effective than PTA in achieving
primary patency, with an expected difference in
primary patency of 15%, after one year. Power analysis
was based on this primary objective. The number of
patients needed in each treatment group was 100, in
order to detect a difference in primary patency of 15%
(75% versus 90% for PTA and bypass surgery,
respectively) with a power of 0.80 and a two-tailed
alpha of 0.05. An intention to treat analysis was used.
The primary patency was defined as the natural
course of the treated femoral artery until occlusion or
re-intervention occurred. Secondary endpoints were
clinical improvement, primary assisted patency, mor-
tality, and adverse events, such as haemorrhage,
infection or stroke. Clinical improvement was defined
as a degree of improvement of at least þ1, compared
to pre-procedure values, according to the SVS/ISCVS
classification. Primary assisted patency was defined as
the history of the treated artery allowing re-interven-
tion for hemodynamic significant re-stenosis to pre-
vent occlusion.
Where appropriate Chi-square test, students T-test
and Mann Whitney U test were used to test baseline
comparability between treatment groups. Kaplan–
Meier survival analysis was used to compare main-
tenance in primary patency.
Results
Between October 1995 and August 1998, 56 patients
were enrolled by 13 participating centres. Because of
this disappointing patient number the National Health
Council decided to terminate the inclusion before the
required number of 200 patients was realised. The
analysis was based on these 56 patients consisting of
19 females and 37 males ranging in age between 42
and 84 years (Table 1). Baseline characteristics were
similar for both treatment groups. Indication for
intervention according to the SVS/ISCVS classification
was severe intermittent claudication category 2 and 3,
predominantly. Overall median lesion length was 9 cm
(range: 5–15 cm). Fifty-one patients had an occlusion
of the femoral artery, whereas five patients were
treated for a stenotic lesion. Median follow-up for all
patients was 703 days (range; 39–1430 days) (Table 2).
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Thirty-one patients were randomly assigned to
PTA; one patient was still on the waiting list at the
end of the study (Fig. 1). Subsequently, 30 patients
underwent the allocated PTA and were analysed. In
seven patients a stent was placed. Two patients were
lost to follow-up after 2 and 3 years, respectively. The
last objective evaluation was used to determine study
endpoints.
Twenty-five patients were randomly assigned to
bypass surgery. Despite informed consent two patients
refused bypass surgery, of whom one patient under-
went PTA after all. The other patient refused further
study participation. In the bypass group 24 patients
were analysed. Twenty-three patients received the
allocated bypass procedure. A reversed vein bypass
was performed 12 times, in situ vein bypass surgery six
times. Four patients received a prosthetic bypass
(polytetrafluoroethylene), as against the study proto-
col. In the bypass group one patient was lost to follow-
up after 3 years, due to a life threatening concomitant
disease.
Primary and primary assisted patency
In three of 30 patients in the PTA group (10%) the
procedure technically failed because the femoral
artery could not be punctured or the occlusion could
not be passed (Table 2). Eighteen patients (60%) had an
occlusion or re-intervention of the target limb, during
follow-up. There were no technical failures in the
bypass group. Seventeen of the 24 bypasses remained
patent during follow-up. Seven patients (29%) had an
occlusion or re-intervention of the bypass at the end of
the study. Thus after bypass surgery there is an
absolute risk reduction for occlusion of 31% (95%
confidence interval (CI): 6–56%) compared to PTA





Age median (range) 68 (45–84) 66 (42–83)
Medical history








Category 1 4 7
Category 2 14 10
Category 3 10 8
Category 4 3 0
Blood systolic pressure
Ankle mmHg (range) 93 (27–170) 93 (42–137)




Length cm (range) 9 (5–15) 9 (5–15)




Fig. 1. Above-knee bypass procedure or percutaneous
transluminal angioplasty in patients with intermittent
claudication; the BASIC-trial. Flow diagram of patient
progress.




Median days (range) 704 (39–1430) 754 (164–1082)
Degree clinical improvement
Rutherford classification












Technical failure 3 0
Occlusion 9 4
Reintervention 1 1
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(Table 3). The hazard ratio for occlusion comparing
PTA with bypass surgery is 2.24 (95% CI: 0.9–5.58).
Life table analysis showed a cumulative 1-year
primary patency after PTA of 43 and 82% after bypass
surgery (Fig. 2).
Taking into account re-interventions 13 out of 30
patients (43%) in the PTA group developed an
uncorrected occlusion. In the bypass group, this
occurred in five patients (21%). Considering secondary
patency, performing a bypass instead of a PTA
resulted in an absolute risk reduction for occlusion of
22% (95% CI: 22–47%) (Table 3). The hazard ratio for
re-occlusion was 2.41 (95% CI: 0.83–6.94) for patients
treated with PTA compared to bypass surgery.
Clinical improvement; SVS/ISCVS classification
Sixteen patients (53%) in the PTA group failed to show
a clinical improvement; in the bypass group eight
patients (33%) did not improve (Table 2). This results
in an absolute difference of clinical success of 20%
(95% CI: 26–46%) in favour of bypass surgery.
Mortality and adverse events
In both treatment groups 30 days mortality was 0%.
Forty days after PTA, one patient underwent major
amputation of the target limb because occlusion of the
crural arteries accidentally occurred during the percu-
taneous procedure. In the bypass group four adverse
events occurred: one patient had a stroke. One patient
developed a serious wound infection in the groin and
two patients had a hematoma, which was treated
conservatively.
Discussion
This paper describes a randomised trial comparing
PTA with bypass surgery for the treatment of an
isolated lesion of the SFA. Although power analysis
showed a required number of 200 patients to detect a
15% difference in treatment success, our inclusion
unfortunately ended with a total number of 56
patients. This is a major drawback limiting the
power of our study. However, the difference in favour
of surgery is impressive. After PTA more than half of
the patients had a re-occlusion with an absolute risk
reduction of 31% (CI: 6–56%) in favour of bypass
surgery. The clinical impact of this reduction is clearly
shown by the number needed to treat. Of three
patients (CI: 2–17) treated with bypass surgery one
additional occlusion is prevented if compared with
PTA. Because of the small patient number the
confidence interval of our primary objective is wide,
but does not reach zero. Therefore, we conclude that
surgery is better than PTA in terms of primary patency.
The disappointing outcome after PTA with a one-
year primary patency of 43% did not correspond with
the patency rates described in literature: 58–76%.7–10
Fig. 2. Kaplan–Meier survival analysis. Primary patency
after PTA and bypass surgery; BASIC trial.
Table 3. Study endpoints: PTA versus bypass surgery; BASIC trial
PTA Bypass Absolute risk reduction Number needed to treat
Number 30 24
Occlusion þ reintervention 18 7
Primary patency 60% 29% 31% (6–56%) 3 (2–17)
Occlusion 13 5
Primary assisted patency 43% 21% 23% (22–47%) 5 (2–1)
Clinical decline* 16 8
53% 33% 20% (26–46%) 5 (2–1)
*According to the SVS/ISCVS classification.
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However, these authors reported a median lesion
length of approximately 5 cm against 9 cm in our
series. The length of the lesion negatively influences
treatment outcome and, therefore, can explain our
results after PTA.11 Secondly, some authors defined
patency by ABI which underestimate re-stenosis or
occlusions compared to our surveillance by duplex
scanning.9,10
More patients in the PTA than in the bypass group
showed a clinical decline. Although there were no
differences in demographic parameters between the
two groups, the patients in the PTA group showed a
slightly higher Rutherford classification. The fact that
no statistical differences could be demonstrated might
be due to small numbers (type II error). Theoretically
this could have biased the results in favour of bypass
surgery. The absolute difference between both study
groups for clinical improvement was 20% (CI: 26–
46%) in favour of surgery. The difference in clinical
effect was less pronounced than our primary objective,
probably because some patients in the PTA group
showed an asymptomatic re-stenosis on duplex scan-
ning. From a clinical point of view one might argue
that our primary endpoint should have been clinical
improvement, another reason to interpret our results
with some caution.
Two earlier randomised trials compared PTA with
bypass surgery.12,13 Both studies described hetero-
geneous patients groups with both iliac- and femoro-
popliteal lesions. Despite the unselected study group
their inclusion rate was approximately 10 patients
each year in two participating centres. We performed
our trial on a homogenous patient group; an isolated
lesion of the femoral artery combined with symptoms
classified according to the SVS/ISCVS classification. In
daily practice patients eligible for our study seem to be
rare; the patient either has an asymptomatic isolated
lesion of the SFA or severe intermittent claudication
based on multilevel peripheral arterial occlusive
disease. We did not register all patients who were
referred to the vascular laboratory for duplex scanning
of the femoral artery, so we do not know the incidence
of patients with an isolated lesion of the femoral artery.
All investigators were closely involved in the
preparation of the study protocol. The centres were
selected for their experience in vascular surgery,
interventional radiology and the availability of a
vascular laboratory. The protocol was adjusted and
approved by all investigators after several central
meetings. During regular site visits at the vascular
laboratory, treadmill test and duplex scanning of the
target limb were standardized and monitored. On a
weekly basis the vascular surgeons, radiologist and
trial co-ordinator reviewed all outpatient angiogra-
phies to screen for eligible study patients. Because of
the large number of participating centres within a
small area we had a unique opportunity to start this
trial supported by the Dutch Health Council. Our strict
inclusion criteria prevented the enrolment of enough
study patients and, therefore, the Dutch Health
Council stopped the study at an earlier date. Despite
18 participating centres our inclusion rate reached
only 20 patients per year. In reflecting this decision, we
obviously wondered greatly if we should have chosen
more flexible criteria. We decided not to adjust these
criteria and continued the follow-up of all included
patients and analysed these data at the study end.
Based on the practical difficulties we encountered, we
doubt whether our primary study question, “which
treatment is the best choice for patients with femor-
opopliteal occlusive disease?” will ever be answered
on a basis of sufficient number of patients. However,
our limited patient volume suggests the superiority of
bypass surgery for long lesions of the SFA.
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